Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
July 03 2024 - 7:00AM
Business Wire
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
(cfDNA) and genetic testing, today announced that its latest
research and data on prenatal and reproductive genetics will be
presented at the 28th International Conference on Prenatal
Diagnosis and Therapy. Hosted by the International Society of
Prenatal Diagnosis (ISPD), the conference will take place July
7-10, 2024, in Boston, MA.
Below is the list of poster presentations
that will be shared at the conference:
- Poster Presentation | Presenter: India Bradley, MS, CGC |
July 8, 3:30 PM ET Importance of evaluation of discordant sex
between SNP-based NIPT and prenatal ultrasound: A case of
congenital lipoid adrenal hyperplasia
- Poster Presentation | Presenter: Peter Benn, DSc | July 8,
3:30 PM ET Chromosome segregation of human non-homologous
Robertsonian translocations: Insights from preimplantation genetic
testing
- Poster Presentation | Presenter: Peter Benn, DSc | July 9,
10:15 AM ET The accuracy of fetal fraction measurement in
non-invasive prenatal screening for fetal aneuploidy using a
SNP-based methodology
Natera will also host an Industry Symposium on July 9, 2024 at
1:00 PM ET, entitled, “The evolution of NIPT: what comes next.” At
the event, Natera Medical Directors – Samantha Leonard, MBBS, PhD,
and Vivienne Souter, MD, MPH – will highlight how early, highly
accurate prenatal screening beyond common chromosome conditions can
optimize outcomes for patients.
“We are pleased to join our collaborators at ISPD to present the
benefits of SNP-based non-invasive prenatal testing and contribute
important biological insights from our experience with
preimplantation genetic testing,” said Sheetal Parmar, MS CGC,
Natera’s senior vice president of medical affairs for women’s
health.
About Natera
NateraTM is a global leader in cell-free DNA and genetic
testing, dedicated to oncology, women’s health, and organ health.
We aim to make personalized genetic testing and diagnostics part of
the standard of care to protect health, and inform earlier, more
targeted interventions that help lead to longer, healthier lives.
Natera’s tests are validated by more than 200 peer-reviewed
publications that demonstrate high accuracy. Natera operates ISO
13485-certified and CAP-accredited laboratories certified under the
Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas
and San Carlos, California. For more information, visit
www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially, including with respect to
whether the results of clinical or other studies will support the
use of our product offerings, the impact of results of such
studies, or our expectations of the benefits of our tests and
product offerings to patients, providers and payers. Additional
risks and uncertainties are discussed in greater detail in "Risk
Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in
other filings Natera makes with the SEC from time to time. These
documents are available at www.natera.com/investors and
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240703897714/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Natera (NASDAQ:NTRA)
Historical Stock Chart
From Oct 2023 to Oct 2024